Comparison of Kaplan-Meier curves revealed significantly lower BCR-free survival rates in PCa patients with aberrant promoter methylation of ADAMTS12, NAALAD2, and PRKCB, as well as ZMIZ1 (p = 0.0023, p = 0.0025, p = 0.0051 and p = 0.0370, respectively; Figure 4B–E). This evidence concerns the gene ADAMTS12 and posterior cortical atrophy.